Research & Development

Is Ekterly a Game-Changer for Hereditary Angioedema Treatment?
Research & Development Is Ekterly a Game-Changer for Hereditary Angioedema Treatment?

Hereditary angioedema (HAE) presents a persistent challenge in the medical world, primarily due to its unpredictable nature and the severe discomfort it causes through spontaneous swelling. This condition stems from genetic factors, leading to fluid accumulation facilitated by bradykinin release.

NeoVaxMI Trial Shows Enhanced Immune Response in Melanoma
Research & Development NeoVaxMI Trial Shows Enhanced Immune Response in Melanoma

The rapid evolution of personalized cancer vaccines promises a transformative era in oncology, as evidenced by the latest research on NeoVaxMI conducted by the Dana-Farber Cancer Institute. This study, focused on patients with untreated advanced or high-risk melanoma, explores advancements in the

Will Budget Cuts Derail NCI's Fight Against Cancer Progress?
Research & Development Will Budget Cuts Derail NCI's Fight Against Cancer Progress?

The escalating battle against cancer faces an unexpected obstacle as federal budget constraints threaten the stability of the National Cancer Institute (NCI), a critical player in this fight. How will these financial stringencies impact the groundbreaking work that has driven monumental progress in

Advancing Diagnosis and Treatment of Neonatal Citrin Deficiency
Research & Development Advancing Diagnosis and Treatment of Neonatal Citrin Deficiency

Neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) is a rare autosomal recessive disorder characterized by a range of clinical and biochemical abnormalities that significantly impact neonatal health. This genetic condition, primarily seen in East Asian populations, is caused by

How Does Hartford HealthCare Define Excellence in Safety?
Research & Development How Does Hartford HealthCare Define Excellence in Safety?

In a landscape where healthcare providers strive for excellence, Hartford HealthCare (HHC) has distinguished itself by earning the 2025 AHA Quest for Quality Prize from the American Hospital Association. This accolade marks a significant achievement, underscoring their exceptional leadership,

CMS Launches Model for Greater Access to Gene Therapies
Research & Development CMS Launches Model for Greater Access to Gene Therapies

The Centers for Medicare & Medicaid Services (CMS) has taken a significant step in healthcare innovation by unveiling a pioneering model designed to improve access to advanced treatments for Medicaid patients affected by sickle cell disease. This initiative, focused on the Cell and Gene Therapy

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later